Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

FDA Approval of Acalabrutinib + BR for 1L MCL: Ph3 ECHO Trial & Subg…

Chan Cheah

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur

Acute GVHD: Demographics, Diagnosis, Pathophysiology, and Advancemen…

City of Hope

A. Salhotra

Treatment Updates and Management of Hodgkin Lymphoma

Integrity CE

A. Niu, D. Wallace, M. Cortese

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Standards of Care and Future Directions in FL

Martin Dreyling

ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients…

2024 ASH Annual Meeting Insights Hub

M. Shadman

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil